Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 25;63(1):2301959.
doi: 10.1183/13993003.01959-2023. Print 2024 Jan.

Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint

Pierre-Régis Burgel  1   2   3 , Isabelle Sermet-Gaudelus  3   4   5 , Emmanuelle Girodon  6 , Reem Kanaan  2   3 , Jean Le Bihan  7 , Natascha Remus  8 , Bruno Ravoninjatovo  9 , Dominique Grenet  10 , Michele Porzio  11 , Véronique Houdouin  12   13 , Laurence Le Clainche-Viala  13 , Isabelle Durieu  3   14   15 , Raphaele Nove-Josserand  3   14 , Jeanne Languepin  16 , Bérangère Coltey  17 , Anne Guillaumot  18 , Camille Audousset  19 , Raphaël Chiron  20 , Laurence Weiss  21 , Isabelle Fajac  12   2   3 , Jennifer Da Silva  2   3 , Clémence Martin  12   2   3 ; French CF Reference Network study group
Affiliations
Free article
Editorial

Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint

Pierre-Régis Burgel et al. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: P-R. Burgel reports support for the present manuscript from Association Vaincre la Mucoviscidose, Société Française de la Mucoviscidose and Filière Maladie Rare Muco CFTR; in addition, P-R. Burgel reports grants from Vertex Pharmaceuticals and GSK, consulting fees from AstraZeneca, Chiesi, GSK, Insmed, Vertex, Viatris and Zambon, and travel support AstraZeneca and Chiesi, outside the submitted work. I. Sermet-Gaudelus reports support for the present manuscript from Vertex Therapeutics and Tavanta; in addition, I. Sermet-Gaudelus reports grants from Vertex Therapeutics and Tavanta, outside the submitted work. I. Durieu and J. Languepin report travel support from Mylan, outside the submitted work. A. Guillaumot reports travel support from Asten, Boehringer Ingelheim, GSK, LFB, CSL Behring, Roche and Menarini, outside the submitted work. C. Audousset reports travel support from Zambon and Viatris, and advisory board participation from Vertex Pharmaceuticals, outside the submitted work. R. Chiron reports travel support from ECFC, and advisory board participation with Zambon and Vertex, outside the submitted work. L. Weiss reports travel support from Viatris, and advisory board participation from Vertex, outside the submitted work. I. Fajac reports grants from AbbVie, Bayer, Boehringer Ingelheim, Insmed, GSK, Vertex Pharmaceuticals and Zambon, consulting fees from AbbVie, Boehringer Ingelheim, Kither Biotech and Vertex Pharmaceuticals, and a leadership role with the European Cystic Fibrosis Society, outside the submitted work. C. Martin reports lecture honoraria from Chiesi, AstraZeneca, Boehringer and GSL, and travel support from Chiesi and Boehringer, outside the submitted work. The remaining authors have no potential conflicts of interest to disclose.

Publication types

LinkOut - more resources